Brief: Vicore Pharma: Drug Candidate C21 Dilates Peripheral Resistance Vessels In Fibrotic Disease
11/03/2021 07:15
March 11 (Reuters) - Vicore Pharma Holding AB VICOR.ST :
* VICORE PHARMA'S DRUG CANDIDATE C21 DILATES PERIPHERAL
RESISTANCE
VESSELS IN FIBROTIC DISEASE
* ANNOUNCES TOP LINE DATA FROM A PHASE II STUDY OF ITS ORAL
ANGIOTENSIN II TYPE 2 RECEPTOR (AT2R) AGONIST C21 IN PATIENTS
WITH SYSTEMIC SCLEROSIS AND RAYNAUD'S PHENOMENON
* AREA UNDER 15 MIN TEMPERATURE CURVE SELECTED AS PRIMARY
ENDPOINT
WAS NOT MET
Source text for Eikon: ID:nWkr8641bn
Further company coverage: VICOR.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587696600;))
Recent news on Vicore Pharma Holding AB
See all newsBrief: Vicore Pharma Holding Q3 Net Revenues Amounted To Sek 0.6 Mln
Brief: Vicore Pharma Holding AB Phase 2B Aspire Trial Of Buloxibutid In Ipf Passes Pre-Planned Futility Analysis, On Track For Mid-2027 Topline Results
Brief: Vicore Pharma Q2 Operating Loss At SEK 150.1 Million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:53 PM
Brief: Vicore Pharma Shares Start Trading In US On July 2